Kareem M. Abu-Elmagd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kareem M. Abu-Elmagd has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- George Vincent Mazariegos
Hillman Center for Pediatric Transplantation Thomas E. Starzl Transplantation Institute, UPMC Children's Hospital of Pittsburgh Pittsburgh Pennsylvania USA
8 shared publications Guilherme Costa
8 shared publicationsKyle Soltys
6 shared publicationsRakesh Sindhi
5 shared publicationsTong Wu
Department of Surgery, Thomas E. Starzl Transplant Institute, University of Pittsburgh, Pittsburgh, PA
5 shared publicationsGeoffrey J. Bond
4 shared publications
Latest Publications
- 1 June 2018
- Published by Oxford University Press (OUP)
Gut Failure after Bariatric Surgery
The gut plays a central role in the control of whole-body energy equilibrium, with obesity and gut failure being the two extremes of the continuum of disrupted energy homeostasis. In the last 25 years there has been a simultaneous evolution of both bariatric surgery for treatment of morbid obesity and surgical rehabilitation for management of gut failure. This chapter addresses gastrointestinal failure with the need for TPN therapy as a true concern among the bariatric surgery population. A new classification is introduced, along with novel surgical procedures, including visceral transplantation, to restore gut homeostasis and nutritional autonomy. In summary, this chapter features the enigma of patients with gut failure after bariatric surgery and underscores the successful management of these complex patients with the application of surgical ingenuity.
- 1 June 2018
- Published by Oxford University Press (OUP)
Gut Failure after Bariatric Surgery
The gut plays a central role in the control of whole-body energy equilibrium, with obesity and gut failure being the two extremes of the continuum of disrupted energy homeostasis. In the last 25 years there has been a simultaneous evolution of both bariatric surgery for treatment of morbid obesity and surgical rehabilitation for management of gut failure. This chapter addresses gastrointestinal failure with the need for TPN therapy as a true concern among the bariatric surgery population. A new classification is introduced, along with novel surgical procedures, including visceral transplantation, to restore gut homeostasis and nutritional autonomy. In summary, this chapter features the enigma of patients with gut failure after bariatric surgery and underscores the successful management of these complex patients with the application of surgical ingenuity.
- Open Access
- 4 September 2012
- Published by Elsevier in American Journal of Transplantation
- Vol. 12 (11) , 3047-3060
Preformed and De Novo Donor Specific Antibodies in Visceral Transplantation: Long-Term Outcome With Special Reference to the Liver
- 4 September 2012
- Published by Elsevier in American Journal of Transplantation
- Vol. 12 (11) , 3047-3060
Open AccessPreformed and De Novo Donor Specific Antibodies in Visceral Transplantation: Long-Term Outcome With Special Reference to the Liver
- 1 September 2012
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 256 (3) , 494-508
Long-Term Survival, Nutritional Autonomy, and Quality of Life After Intestinal and Multivisceral Transplantation
To assess long-term survival, graft function, and health-related quality of life (QOL) after visceral transplantation. Despite continual improvement in early survival, the long-term therapeutic efficacy of visceral transplantation has yet to be defined. A prospective cross-sectional study was performed on 227 visceral allograft recipients who survived beyond the 5-year milestone. Clinical data were used to assess outcome including graft function and long-term survival predictors. The socioeconomic milestones and QOL measures were assessed by clinical evaluation, professional consultation, and validated QOL inventory. Of 376 recipients, 227 survived beyond 5 years, with conditional survival of 75% at 10 years and 61% at 15 years. With a mean follow-up of 10 ± 4 years, 177 (92 adults, 85 children) are alive, with 118 (67%) recipients 18 years or older. Nonfunctional social support and noninclusion of the liver in the visceral allograft are the most significant survival risk factors. Nutritional autonomy was achievable in 160 (90%) survivors, with current serum albumin level of 3.7 ± 0.5 gm/dL and body mass index of 25 ± 6 kg/m(2). Despite coexistence or development of neuropsychiatric disorders, most survivors were reintegrated to society with self-sustained socioeconomic status. In parallel, most of the psychological, emotional, and social QOL measures significantly (P < 0.05) improved after transplantation. Current morbidities with potential impact on global health included dysmotility (59%), hypertension (37%), osteoporosis (22%), and diabetes (11%), with significantly (P < 0.05) higher incidence among adult recipients. With new tactics to further improve long-term survival including social support measures, visceral transplantation has achieved excellent nutritional autonomy and good QOL.
- 1 September 2012
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 256 (3) , 494-508
Long-Term Survival, Nutritional Autonomy, and Quality of Life After Intestinal and Multivisceral Transplantation
To assess long-term survival, graft function, and health-related quality of life (QOL) after visceral transplantation. Despite continual improvement in early survival, the long-term therapeutic efficacy of visceral transplantation has yet to be defined. A prospective cross-sectional study was performed on 227 visceral allograft recipients who survived beyond the 5-year milestone. Clinical data were used to assess outcome including graft function and long-term survival predictors. The socioeconomic milestones and QOL measures were assessed by clinical evaluation, professional consultation, and validated QOL inventory. Of 376 recipients, 227 survived beyond 5 years, with conditional survival of 75% at 10 years and 61% at 15 years. With a mean follow-up of 10 ± 4 years, 177 (92 adults, 85 children) are alive, with 118 (67%) recipients 18 years or older. Nonfunctional social support and noninclusion of the liver in the visceral allograft are the most significant survival risk factors. Nutritional autonomy was achievable in 160 (90%) survivors, with current serum albumin level of 3.7 ± 0.5 gm/dL and body mass index of 25 ± 6 kg/m(2). Despite coexistence or development of neuropsychiatric disorders, most survivors were reintegrated to society with self-sustained socioeconomic status. In parallel, most of the psychological, emotional, and social QOL measures significantly (P < 0.05) improved after transplantation. Current morbidities with potential impact on global health included dysmotility (59%), hypertension (37%), osteoporosis (22%), and diabetes (11%), with significantly (P < 0.05) higher incidence among adult recipients. With new tactics to further improve long-term survival including social support measures, visceral transplantation has achieved excellent nutritional autonomy and good QOL.
- 1 January 2012
- p. 155-66
A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation.
In 2001, we hypothesized that recipient pretreatment with a single-dose of an anti-lymphoid depleting agent followed by tacrolimus monotherapy could promote alloengraftment with minimal long-term immunosuppression. As of November 2010, the protocol was applied to 175 adults: 46 (26%) received rATG (5 mg/kg) and 129 (74%) received alemtuzumab (30 mg). Targeted 12-hour tacrolimus trough levels were 10-15 ng/mL followed by attempts of spaced-dose reduction in selected patients. Steroids were limited to recipients with serum sickness, adrenal insufficiency, and rejection. With a 13% re-transplantation rate, overall 1-, 5-, and 10-year survival was 93%, 70%, and 50% for patients with respective graft survival of 86%, 57%, and 48%. Rejection and infection continued to be leading causes of graft loss. With better patient (p = 0.04) and graft (p = 0.03) survival among alemtuzumab-pretreated patients, cumulative risk of end-stage acute/chronic rejection was similar (p = 0.4) between both antibody cohorts. Tacrolimus spaced-dose reduction was sustainable in 56% of current survivors with 40% of the total population continuing to be steroid-free. However, few of these recipients experienced life-threatening infections and de-novo malignancy. Despite an increase in long-term survival and achievement of partial 'prope' tolerance reported herein, innovative immunosuppressive strategies along with availability of reliable tolerance assays are still required to further improve long-term visceral allograft acceptance.
- 1 January 2012
- p. 155-66
A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation.
In 2001, we hypothesized that recipient pretreatment with a single-dose of an anti-lymphoid depleting agent followed by tacrolimus monotherapy could promote alloengraftment with minimal long-term immunosuppression. As of November 2010, the protocol was applied to 175 adults: 46 (26%) received rATG (5 mg/kg) and 129 (74%) received alemtuzumab (30 mg). Targeted 12-hour tacrolimus trough levels were 10-15 ng/mL followed by attempts of spaced-dose reduction in selected patients. Steroids were limited to recipients with serum sickness, adrenal insufficiency, and rejection. With a 13% re-transplantation rate, overall 1-, 5-, and 10-year survival was 93%, 70%, and 50% for patients with respective graft survival of 86%, 57%, and 48%. Rejection and infection continued to be leading causes of graft loss. With better patient (p = 0.04) and graft (p = 0.03) survival among alemtuzumab-pretreated patients, cumulative risk of end-stage acute/chronic rejection was similar (p = 0.4) between both antibody cohorts. Tacrolimus spaced-dose reduction was sustainable in 56% of current survivors with 40% of the total population continuing to be steroid-free. However, few of these recipients experienced life-threatening infections and de-novo malignancy. Despite an increase in long-term survival and achievement of partial 'prope' tolerance reported herein, innovative immunosuppressive strategies along with availability of reliable tolerance assays are still required to further improve long-term visceral allograft acceptance.
- 31 August 2011
- Published by Elsevier in Transplant Immunology
- Vol. 25 (2-3) , 112-118
Effects of immunosuppressive therapy after experimental small bowel transplantation in rats
- 31 August 2011
- Published by Elsevier in Transplant Immunology
- Vol. 25 (2-3) , 112-118
Effects of immunosuppressive therapy after experimental small bowel transplantation in rats
- 27 June 2011
- Published by Wolters Kluwer Health in Transplantation
- Vol. 91 (12) , 1417-1423
Modified Multivisceral Transplantation With Spleen-Preserving Pancreaticoduodenectomy for Patients With Familial Adenomatous Polyposis “Gardner's Syndrome”
Background. Liver-sparing “modified” multivisceral transplantation (MMVTx) has recently been more used for patients with diffuse gastrointestinal disorders and preserved hepatic functions. Evisceration techniques with preservation of native spleen were also introduced to reduce risk of posttransplant lymphoproliferative disorders. This study focuses on the indications of MMVTx for patients with familial adenomatous polyposis (FAP) and the technical feasibility of performing spleen-preserving pancreaticoduodenectomy (SPPD). Methods. Between 1993 and 2009, 10 FAP patients required MMVTx. Nine were adults and one was a child, with a female:male ratio of 1:1. Results. Short gut with duodenal adenomatosis and extensive desmoid tumors with pancreaticoduodenal involvement dictated need for MMVTx. SPPD was technically feasible in four recipients, and conventional evisceration including splenectomy was performed in remaining six recipients. With an overall cumulative survival of 90% at 1 year and 77% at 10 years, all SPPD recipients were alive with no single example of posttransplant lymphoproliferative disorder, graft-versus-host disease, or chronic rejection. However, SPPD was associated with an increase (P>0.3) in total ischemia time, operative time, and packed red blood cells requirement but with shorter (P=0.6) length of hospital stay. With a mean follow-up of 50±45 months (range 18–128 months), none of the 10 recipients experienced intraabdominal desmoid tumor recurrence or developed de novo visceral allograft neoplasm. Conclusion. MMVTx is a valuable therapeutic option for FAP patients who are in need for visceral transplantation with pathologic involvement of the pancreaticoduodenal complex. SPPD is technically feasible, and efforts should always be made to preserve native spleen because of the reported herein therapeutic advantages.
- 27 June 2011
- Published by Wolters Kluwer Health in Transplantation
- Vol. 91 (12) , 1417-1423
Modified Multivisceral Transplantation With Spleen-Preserving Pancreaticoduodenectomy for Patients With Familial Adenomatous Polyposis “Gardner's Syndrome”
Background. Liver-sparing “modified” multivisceral transplantation (MMVTx) has recently been more used for patients with diffuse gastrointestinal disorders and preserved hepatic functions. Evisceration techniques with preservation of native spleen were also introduced to reduce risk of posttransplant lymphoproliferative disorders. This study focuses on the indications of MMVTx for patients with familial adenomatous polyposis (FAP) and the technical feasibility of performing spleen-preserving pancreaticoduodenectomy (SPPD). Methods. Between 1993 and 2009, 10 FAP patients required MMVTx. Nine were adults and one was a child, with a female:male ratio of 1:1. Results. Short gut with duodenal adenomatosis and extensive desmoid tumors with pancreaticoduodenal involvement dictated need for MMVTx. SPPD was technically feasible in four recipients, and conventional evisceration including splenectomy was performed in remaining six recipients. With an overall cumulative survival of 90% at 1 year and 77% at 10 years, all SPPD recipients were alive with no single example of posttransplant lymphoproliferative disorder, graft-versus-host disease, or chronic rejection. However, SPPD was associated with an increase (P>0.3) in total ischemia time, operative time, and packed red blood cells requirement but with shorter (P=0.6) length of hospital stay. With a mean follow-up of 50±45 months (range 18–128 months), none of the 10 recipients experienced intraabdominal desmoid tumor recurrence or developed de novo visceral allograft neoplasm. Conclusion. MMVTx is a valuable therapeutic option for FAP patients who are in need for visceral transplantation with pathologic involvement of the pancreaticoduodenal complex. SPPD is technically feasible, and efforts should always be made to preserve native spleen because of the reported herein therapeutic advantages.
- 17 September 2010
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 14 (11) , 1709-1721
Modified “Liver-Sparing” Multivisceral Transplant with Preserved Native Spleen, Pancreas, and Duodenum: Technique and Long-Term Outcome
- 17 September 2010
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 14 (11) , 1709-1721
Modified “Liver-Sparing” Multivisceral Transplant with Preserved Native Spleen, Pancreas, and Duodenum: Technique and Long-Term Outcome
- Open Access
- 3 September 2010
- Published by Elsevier in American Journal of Transplantation
- Vol. 10 (10) , 2331-2340
Skeletal Integrity and Visceral Transplantation
- 3 September 2010
- Published by Elsevier in American Journal of Transplantation
- Vol. 10 (10) , 2331-2340
Open AccessSkeletal Integrity and Visceral Transplantation
- Open Access
- 1 August 2010
- Published by Elsevier in American Journal of Transplantation
- Vol. 10 (8) , 1940-1946
An Innovative Sphincter Preserving Pull-Through Technique with En Bloc Colon and Small Bowel Transplantation
- 1 August 2010
- Published by Elsevier in American Journal of Transplantation
- Vol. 10 (8) , 1940-1946
Open AccessAn Innovative Sphincter Preserving Pull-Through Technique with En Bloc Colon and Small Bowel Transplantation
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
430 Multivisceral Transplantation With Preservation of Native Liver, Pancreaticoduodenal Complex and Spleen. Indications and Long-Term Outcome
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
430 Multivisceral Transplantation With Preservation of Native Liver, Pancreaticoduodenal Complex and Spleen. Indications and Long-Term Outcome